ChemPartner(SZ:300149)2022-12-04 10:26Group 1: Investor Relations Activity - Quantum High-Tech conducted an investor relations activity on January 18, 2018, involving specific object research and discussions with various securities firms [2][3][4] - Participants included representatives from multiple securities firms such as Guotai Junan, Minsheng Securities, and others [2][3] Group 2: Acquisition of Ruizhi Chemical - Quantum High-Tech is planning to acquire 90% of Ruizhi Chemical's shares, discussing the transaction details and business operations during the meeting [4][5] - The company is considering renaming Ruizhi Chemical to Ruizhi Biology due to its significant business in biological research and development [4] Group 3: Business Development and Strategy - The biological business has been a highlight over the past three to four years, with a growing market share for biological drugs globally [4][6] - Ruizhi Chemical's CDMO department currently employs nearly 200 people, indicating a need for further recruitment and talent retention strategies [4][5] - The company aims to enhance its capabilities in the CDMO sector, focusing on both domestic and international markets by 2019 [6] Group 4: Future Plans and Market Position - Post-acquisition, the board of Ruizhi Chemical will include three directors appointed by Quantum High-Tech, maintaining the existing management structure while expanding talent [5][6] - The company plans to balance the development of its CRO and CMO businesses, with a focus on the growing biological drug sector [6]